Related Experiment Video
Updated: Nov 4, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Treatment for Severe Asthma in Children: What About Biologics?
Insights
Severe asthma in children, a common childhood pulmonary disease, often resists standard treatments. New biologic therapies targeting inflammation show promise for improving outcomes in pediatric severe asthma patients.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
Background:
- Asthma is the most common pulmonary disease in children aged 5-17.
- Severe asthma affects 5-10% of pediatric patients, characterized by poor control and significant morbidity.
- Current intensive therapies are often insufficient for severe pediatric asthma cases.
Purpose of the Study:
- To review biologic agents approved for treating severe asthma in children.
- To highlight advancements in managing pediatric severe asthma.
Main Methods:
- Literature review of approved biologic agents for pediatric severe asthma.
- Analysis of treatment targets and efficacy in pediatric populations.
Main Results:
- Several biologic agents targeting asthma inflammation mediators are now available.
- These biologics offer potential for improved asthma control and outcomes in children.
Conclusions:
- Biologic therapies represent a significant advancement in managing severe pediatric asthma.
- Targeted biologic treatments are expected to enhance quality of life and reduce exacerbations in children with severe asthma.
Abstract:
Asthma is the most common pulmonary disease in children age 5 to 17 years. Asthma is characterized by chronic airway inflammation and heterogeneous clinical phenotypes. A small proportion of patients (approximately 5% to 10%) diagnosed with severe asthma are unable to achieve asthma control even with intensive therapy. Severe asthma in children is characterized by poor asthma control, uncontrolled symptoms, poor quality of life, disrupted school-related activities and increased risk of exacerbations, health care use, and morbidities due to asthma. Several new biologic agents targeting the mediators of asthma inflammation that are now approved are likely to improve asthma outcomes in children with severe asthma. This article outlines the various biologic agents currently approved for use in children. [.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.